SPAC trading pops deflate as ‘exuberance and greed’ depart By Reuters

<iframe src=”//rcm-na.amazon-adsystem.com/e/cm?o=1&p=22&l=ur1&category=homegarden&banner=02NMTC702K4D0VHE1SR2&f=ifr&linkID=17e0b4ac3a719000706e772761d8ae0e&t=forexz-20&tracking_id=forexz-20″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>

© Reuters. FILE PHOTO: Bull and bear symbols for successful and bad trading are seen in front of the German stock exchange (Deutsche Boerse) in Frankfurt

(Refiles to add dropped word in final sentence)

By Joshua Franklin and Krystal Hu

(Reuters) – Wall Street’s appetite for new special purpose acquisition companies (SPACs) shows signs of waning.

First-day trading pops, or share price rises, for SPACs were commonplace earlier this year with gains rising to over 30% but have faded in March amid a broader selloff in many companies that have agreed to go public through a SPAC merger.

All but one of the 15 SPACs that started trading this week closed below their initial public offering (IPO) price of $10 per unit on their first day of trading, according to financial markets platform Dealogic and market data. Many other deals are also trading below their IPO prices.

SPACs are shell companies with no operating business and that raise money with the purpose of merging with an operating company to take public.

SPAC stocks have traditionally traded close to their $10 IPO price until they announce a merger. However, exuberance over the last few months resulted in many being bid up on speculation that the SPAC would ultimately merge with a company that would be well-received by the market.

So far this month, the biggest first-day pop has been a 3.5% gain for Supernova Partners Acquisition Co II Ltd on March 1, compared with a January high of 32.5% for Altimeter Growth Corp 2 and a February high of 24.9% for CM Life Sciences II Inc.

The decline in enthusiasm has set in a week after news that SPACs had surpassed the $83.4 billion through IPOs the sector raised in all of 2020, which had been a record year.

Some 294 SPACs have raised $95.7 billion so far this year, with a further 229 seeking a little over $58 billion in the pre-IPO stage, according to information provider SPAC Research.

“We’re seeing so many SPACs. There’s a finite amount of capital at the IPO level that is available for SPACs and there’s not an endless pool of capital,” said Harris Arch, SPAC Portfolio Manager at asset management firm DuPont (NYSE:) Capital.

The rocky performance of new deals has the potential to slow the pace of new IPOs given that investors can buy existing SPACs below $10 instead of purchasing new SPACs at a $10 price.

Investors have also voiced concerns over the market reaction to SPACs when they announce merger targets. The likes of Thoma Bravo Advantage and Jaws Spitfire Acquisition Corp have seen their shares fall after confirming merger targets.

“The market has sold off tech, a lot of the SPACs are tech-focused. People are also beginning to question the euphoria and retail investors are unable to keep up with all these names,” said Barry Sternlicht, chairman of Starwood Capital Group and of Jaws Spitfire.

This is in stark contrast to double-digit gains on many announcements only weeks ago.

“The frenzy and the exuberance and greed we saw a couple months ago have quickly left the market,” Arch said. (This story refiles to add dropped word in final sentence)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


*